Semax: mechanism of action, studies and open questions

What is Semax?

Semax is a synthetic peptide made of seven amino acids. It is based on a fragment of ACTH (adrenocorticotropic hormone) and was stabilized by adding extra amino acids. It was developed at Russian research institutes, and in Russia it is approved for stroke as well as cognitive and neurological disorders. Outside Russia it is sold in the wellness market and as a “research peptide” for boosting cognitive performance and protecting nerve cells. In the US it is not an approved drug. Source

How is Semax supposed to work?

Semax is thought to have cognitive and neuroprotective effects by raising growth signals for nerve cells, such as BDNF and NGF, and by influencing messenger systems in the brain. These effects have been described mainly in animal and laboratory studies 1. A proposed mechanism is not the same thing as a proven benefit in humans.

Is Semax FDA-approved?

No. Semax has no FDA approval. In Russia it is approved for stroke and cognitive indications. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted, in a non-binding vote, in favor of allowing it to be compounded under Section 503A. FDA staff disagreed, citing insufficient evidence 2. A vote like this is a recommendation, not a drug approval. On October 30, 2026, HHS announced a draft, nonbinding enforcement-discretion policy for certain single-ingredient peptides under specified conditions. Appendix B covers Semax free base for intranasal use; this is distinct from FDA approval and final bulk-list rulemaking. HHS policy Federal Register notice

What does the research show?

Human studies exist, but their quality is limited. Russian studies have reported on its use in stroke, transient ischemic attack, cognitive impairment and eye diseases. Most of these studies are:

• small,

• methodologically weak,

• limited to a single country,

• often linked to the institutions that developed the peptide, and rarely replicated independently.

An analytical review 3 notes that these peptides have not completed clinical trial programs that meet Western regulatory standards. By those standards, the available data do not establish efficacy.

How does Semax differ from Selank?

Semax and Selank are both synthetic peptides of seven amino acids developed at Russian research institutes. They differ mainly in the natural molecule they are derived from and in the uses approved in Russia. The table compares these differences. Source

The descriptions of how either peptide works rest mostly on animal and laboratory studies. A clear clinical benefit in humans has not been demonstrated for either one.

Neither peptide is FDA-approved. The advisory vote on Semax does not change that.

The human studies of both peptides share similar limitations: they are small, come mostly from Russia, were often carried out at the institutions that developed the peptides, and have not been independently replicated. An analytical review 3 points to the lack of clinical trial programs that meet Western regulatory standards. The evidence supports neither established efficacy nor the superiority of one peptide over the other.

Frequently asked questions

Is Semax FDA-approved?

No. Semax is not FDA-approved in the United States. Its Russian registration is neither FDA approval nor equivalent US recognition. HHS announced a separate conditional enforcement-discretion policy on October 30, 2026, covering specified single-ingredient peptides, including Semax free base for intranasal use. The Federal Register describes the policy as a draft and nonbinding; it is not approval of a medicine. Source HHS policy Federal Register notice

What uses of Semax have been studied in Russia?

In the Russian clinical setting, Semax has been studied in rehabilitation after ischemic stroke 6, in chronic cerebrovascular insufficiency 7 and in diseases of the optic nerve 8. This research took place outside the US approval system. It provides no basis for FDA approval; Semax has no approved indication in the US.

What are the side effects of Semax?

Safety data in humans are sparse. Most published Semax studies did not report side effects. The clinical information is not sufficient to describe the safety profile reliably 5. One entry in the FDA’s adverse event database describes eye pain and burning after using Semax nasal drops bought online. Possible anticoagulant effects described in one study also suggest a theoretical risk of bleeding. Long-term data and independent Western pharmacovigilance data are missing, so the known side effects can only be captured incompletely. Any new or persistent symptoms during use should be checked by a doctor.

How does Semax work at the molecular level?

In rat studies, Semax increased the activity of the BDNF and NGF genes in the cerebral cortex after an experimentally induced stroke 4. BDNF supports the survival of nerve cells and synaptic plasticity. Its increased production is tied especially closely to the effects described in Russian publications. In rodents, Semax also increased serotonin activity and boosted amphetamine-induced dopamine release 9. In a small resting-state fMRI study 10 of 24 healthy volunteers, one subcomponent of the default mode network was larger after intranasal Semax than after placebo. This is an imaging signal of activity in the central nervous system, not proof of clinical benefit.

Is Semax available without a prescription?

Semax is not an FDA-approved over-the-counter medicine. The October 2026 HHS policy describes conditional enforcement discretion for patient-specific compounding of Semax free base for intranasal use. It is limited to single-ingredient products that satisfy its identity, manufacturing, testing, labeling, reporting, and other conditions. It does not establish that a particular seller or product complies. Unregulated research-chemical sources carry uncertain composition, quality, and sterility. HHS policy Federal Register notice

How strong is the evidence on Semax?

The research is largely concentrated in one scientific community, geographically and linguistically. The most informative human data come from Russian clinical studies, mainly in stroke. These include a 1997 comparative study in acute ischemic stroke 11 with 110 patients, 30 of them on Semax and 80 in the control group, and a 2018 study of 110 patients after stroke 6. The latter used two 10-day treatment cycles at 6,000 mcg/day. The studies appeared in peer-reviewed journals, some of them listed on PubMed. However, they come from a single national research setting and have not been independently replicated in Western studies. Genomic, transcriptomic and proteomic work describes possible molecular foundations for the reported effects. So there are published clinical data in humans, but less independent confirmation than FDA approval would require.

Are peptides legal in 2026?

That depends on the specific substance, formulation, route, and supply chain. The May 14, 2026 FDA nomination list is a historical record, not the whole current regulatory picture. The July 24 advisory recommendation for Semax, reported as an 8-to-5 vote, was nonbinding. On October 30, HHS announced a separate conditional enforcement-discretion policy while bulk-list rulemaking continues. Appendix B addresses Semax free base for intranasal use, and the policy requires a single active ingredient, a patient-specific prescription, verified manufacturing and testing, appropriate labeling, adverse-event reporting, and compliance with other applicable requirements. The Federal Register describes a draft, nonbinding policy; it neither grants FDA approval nor creates a binding right. A clinician and pharmacist should check the current federal and state requirements for a particular preparation. Source Source HHS policy Federal Register notice

Studies at a glance

Feature	Semax	Selank
Parent molecule	A fragment of the hormone ACTH.	A stabilized analog of the natural immunomodulatory peptide tuftsin.
Approval in Russia	Stroke as well as cognitive and neurological disorders.	Anti-anxiety agent.
Proposed mechanism	Boosts nerve growth signals such as BDNF and NGF 4.	Influences the enkephalin and GABA systems as well as serotonin metabolism.
US compounding review	July 2026 advisory recommendation; October HHS policy describes conditional enforcement discretion for single-ingredient Semax free base used intranasally. This is not FDA approval.	Selank is not among the six substances in that HHS policy. HHS policy Federal Register notice

Source Source

References provided in the source article

Sources: a preclinical study of semax (Glazova et al., Neuropeptides, 2020, DOI: 10.1016/j.npep.2020.102114 1 ) and an analytical review of research peptides (Esposito et al., Drug Testing and Analysis, 2020, DOI: 10.1002/dta.2717 3 ), indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote.

Provenance and editorial review status

Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.